Wells Fargo & Co lowered shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a market perform rating to an underperform rating in a report published on Friday, January 5th, MarketBeat reports. The brokerage currently has $17.00 target price on the stock, down from their prior target price of $19.58.
Several other brokerages have also recently issued reports on TEVA. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a report on Tuesday, December 5th. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a buy rating in a report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Thursday, October 26th. Morgan Stanley set a $15.00 price target on Teva Pharmaceutical Industries and gave the stock an underweight rating in a research note on Thursday, October 5th. Finally, Mizuho reaffirmed a hold rating and issued a $15.00 price target on shares of Teva Pharmaceutical Industries in a research note on Monday, October 30th. Eight analysts have rated the stock with a sell rating, fifteen have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $21.17.
Shares of Teva Pharmaceutical Industries (TEVA) traded up $0.33 on Friday, reaching $22.07. 40,553,199 shares of the company were exchanged, compared to its average volume of 24,050,100. The stock has a market capitalization of $22,190.00, a P/E ratio of -3.76, a P/E/G ratio of 1.58 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $37.94.
Large investors have recently made changes to their positions in the stock. Exane Derivatives bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $571,000. Korea Investment CORP lifted its holdings in Teva Pharmaceutical Industries by 14.3% in the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after purchasing an additional 30,674 shares in the last quarter. Financial Counselors Inc. lifted its holdings in Teva Pharmaceutical Industries by 5.7% in the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after purchasing an additional 7,571 shares in the last quarter. Private Capital Management Inc. lifted its holdings in Teva Pharmaceutical Industries by 51.3% in the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after purchasing an additional 8,850 shares in the last quarter. Finally, Lockheed Martin Investment Management Co. purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $317,000. Institutional investors own 51.96% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Rating Lowered to Underperform at Wells Fargo & Co” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/wells-fargo-co-downgrades-teva-pharmaceutical-industries-teva-to-underperform/1820691.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.